|Awarded On||August 16, 2017|
|Title||Improving the Outcome of Stem Cell Transplants for Cancer Treatment Using Multi-Virus Specific T cells|
|Program||Product Development Research|
|Award Mechanism||Texas Company Product Development Awards|
|Principal Investigator/Program Director||Ann Leen|
|Cancer Sites||Leukemia, Lymphoma|
Many patients with cancer are cured by a stem cell transplant from a donor's bone marrow, umbilical cord blood, or peripheral blood. However, because these patients must endure a period of months before their immune system recovers, severe viral infections afflict over 70% of patients following transplant. These viral infections cause pain, organ damage, prolonged hospitalization, and even death. In fact, viral infections are now the most common severe complication related to stem cell transplantation. Because of the risk of infection, many other cancer patients cannot receive a transplant, and thus lose their best hope for cure.
ViraCyte has developed revolutionary new T-cell therapies th...